uniQure N.V. Pre-Tax Income
uniQure N.V. (QURE) reported Pre-Tax Income of -$53.05 million for the 3-month period ending 2026-03-31, per its 10-Q filed 2026-05-05.
Financial Statements › Income Statement › Pre-tax Income
us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest · last filed 2026-05-05
- uniQure N.V. income (loss) from continuing operations before income taxes, noncontrolling interest for the quarter ending 2026-03-31 was -$53.05M.
- uniQure N.V. income (loss) from continuing operations before income taxes, noncontrolling interest for the quarter ending 2025-12-31 was -$41.00M.
- uniQure N.V. income (loss) from continuing operations before income taxes, noncontrolling interest for the quarter ending 2025-09-30 was -$71.90M.
- uniQure N.V. income (loss) from continuing operations before income taxes, noncontrolling interest for the quarter ending 2025-06-30 was -$37.29M.
- uniQure N.V. income (loss) from continuing operations before income taxes, noncontrolling interest for fiscal 2025 was -$193.34M.
- uniQure N.V. income (loss) from continuing operations before income taxes, noncontrolling interest for fiscal 2024 was -$237.13M.
- uniQure N.V. income (loss) from continuing operations before income taxes, noncontrolling interest for fiscal 2023 was -$306.56M.
- uniQure N.V. income (loss) from continuing operations before income taxes, noncontrolling interest for fiscal 2022 was -$128.26M, a 138.54% decline from fiscal 2021.
| Period end | Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 3 month | Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 6 month | Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 9 month | Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 12 month |
|---|---|---|---|---|
| 2026-03-31 | -$53.05M 10-Q · filed 2026-05-05 | -$94.05M derived: sum of 2 quarters · filed 2026-05-05 | -$165.95M derived: sum of 3 quarters · filed 2026-05-05 | -$203.25M derived: sum of 4 quarters · filed 2026-05-05 |
| 2025-12-31 | -$41.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | -$112.91M derived: sum of 2 quarters · filed 2026-03-02 | -$150.20M derived: sum of 3 quarters · filed 2026-03-02 | -$193.34M 10-K · filed 2026-03-02 |
| 2025-09-30 | -$71.90M 10-Q · filed 2025-11-10 | -$109.20M derived: sum of 2 quarters · filed 2025-11-10 | -$152.34M 10-Q · filed 2025-11-10 | -$224.74M derived: sum of 4 quarters · filed 2026-05-05 |
| 2025-06-30 | -$37.29M 10-Q · filed 2025-07-29 | -$80.44M 10-Q · filed 2025-07-29 | -$152.84M derived: sum of 3 quarters · filed 2026-05-05 | -$197.25M derived: sum of 4 quarters · filed 2026-05-05 |
| 2025-03-31 | -$43.14M 10-Q · filed 2026-05-05 | -$115.55M derived: sum of 2 quarters · filed 2026-05-05 | -$159.96M derived: sum of 3 quarters · filed 2026-05-05 | -$215.31M derived: sum of 4 quarters · filed 2026-05-05 |
| 2024-12-31 | -$72.41M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | -$116.81M derived: sum of 2 quarters · filed 2026-03-02 | -$172.16M derived: sum of 3 quarters · filed 2026-03-02 | -$237.13M 10-K · filed 2026-03-02 |
| 2024-09-30 | -$44.41M 10-Q · filed 2025-11-10 | -$99.76M derived: sum of 2 quarters · filed 2025-11-10 | -$164.72M 10-Q · filed 2025-11-10 | -$234.89M derived: sum of 4 quarters · filed 2026-03-02 |
| 2024-06-30 | -$55.35M 10-Q · filed 2025-07-29 | -$120.31M 10-Q · filed 2025-07-29 | -$190.49M derived: sum of 3 quarters · filed 2026-03-02 | -$280.13M derived: sum of 4 quarters · filed 2026-03-02 |
| 2024-03-31 | -$64.96M 10-Q · filed 2025-05-09 | -$135.13M derived: sum of 2 quarters · filed 2026-03-02 | -$224.77M derived: sum of 3 quarters · filed 2026-03-02 | -$293.08M derived: sum of 4 quarters · filed 2026-03-02 |
| 2023-12-31 | -$70.17M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | -$159.81M derived: sum of 2 quarters · filed 2026-03-02 | -$228.12M derived: sum of 3 quarters · filed 2026-03-02 | -$306.56M 10-K · filed 2026-03-02 |
| 2023-09-30 | -$89.64M 10-Q · filed 2024-11-05 | -$157.95M derived: sum of 2 quarters · filed 2024-11-05 | -$236.38M 10-Q · filed 2024-11-05 | -$229.78M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | -$68.31M 10-Q · filed 2024-08-01 | -$146.75M 10-Q · filed 2024-08-01 | -$140.15M derived: sum of 3 quarters · filed 2025-02-27 | -$188.33M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | -$78.43M 10-Q · filed 2024-05-07 | -$71.83M derived: sum of 2 quarters · filed 2025-02-27 | -$120.02M derived: sum of 3 quarters · filed 2025-02-27 | -$159.40M derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | $6.60M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | -$41.59M derived: sum of 2 quarters · filed 2025-02-27 | -$80.97M derived: sum of 3 quarters · filed 2025-02-27 | -$128.26M 10-K · filed 2025-02-27 |
| 2022-09-30 | -$48.19M 10-Q · filed 2023-11-07 | -$87.56M derived: sum of 2 quarters · filed 2023-11-07 | -$134.86M 10-Q · filed 2023-11-07 | -$126.99M derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-06-30 | -$39.38M 10-Q · filed 2023-08-01 | -$86.67M 10-Q · filed 2023-08-01 | -$78.81M derived: sum of 3 quarters · filed 2024-02-28 | -$115.25M derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-03-31 | -$47.29M 10-Q · filed 2023-05-09 | -$39.43M derived: sum of 2 quarters · filed 2024-02-28 | -$75.87M derived: sum of 3 quarters · filed 2024-02-28 | $326.86M derived: sum of 4 quarters · filed 2024-02-28 |
| 2021-12-31 | $7.87M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | -$28.58M derived: sum of 2 quarters · filed 2024-02-28 | $374.15M derived: sum of 3 quarters · filed 2024-02-28 | $332.81M 10-K · filed 2024-02-28 |
| 2021-09-30 | -$36.44M 10-Q · filed 2022-11-02 | $366.28M derived: sum of 2 quarters · filed 2022-11-02 | $324.94M 10-Q · filed 2022-11-02 | $307.82M derived: sum of 4 quarters · filed 2023-02-27 |
| 2021-06-30 | $402.73M 10-Q · filed 2022-08-08 | $361.38M 10-Q · filed 2022-08-08 | $344.26M derived: sum of 3 quarters · filed 2023-02-27 | $290.49M derived: sum of 4 quarters · filed 2023-02-27 |
| 2021-03-31 | -$41.34M 10-Q · filed 2022-05-02 | -$58.46M derived: sum of 2 quarters · filed 2023-02-27 | -$112.24M derived: sum of 3 quarters · filed 2023-02-27 | -$154.79M derived: sum of 4 quarters · filed 2023-02-27 |
| 2020-12-31 | -$17.12M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-27 | -$70.89M derived: sum of 2 quarters · filed 2023-02-27 | -$113.44M derived: sum of 3 quarters · filed 2023-02-27 | -$141.44M 10-K · filed 2023-02-27 |
| 2020-09-30 | -$53.77M 10-Q · filed 2021-10-25 | -$96.33M derived: sum of 2 quarters · filed 2021-10-25 | -$124.33M 10-Q · filed 2021-10-25 | |
| 2020-06-30 | -$42.55M 10-Q · filed 2021-07-26 | -$70.55M 10-Q · filed 2021-07-26 | ||
| 2019-12-31 | -$124.20M 10-K · filed 2022-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 |